# Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

> **NCT04878484** · PHASE1 · WITHDRAWN · sponsor: **Athenex, Inc.**

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** TCRT-ESO-A2

## Key facts

- **NCT ID:** NCT04878484
- **Lead sponsor:** Athenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08-11
- **Primary completion:** 2022-10
- **Final completion:** 2024-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Poor recruitment
- **Last updated:** 2022-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04878484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04878484, "Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04878484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*